• Radhakrishnan Narayanaswamy Department of Biotechnology, Vel Tech Rangarajan Dr. Sagunthala R and D Institute of Science and Technology, Avadi, Chennai – 600 062, Tamil Nadu, India.
  • Merry Hailu Department of Biotechnology, Vel Tech Rangarajan Dr. Sagunthala R and D Institute of Science and Technology, Avadi, Chennai – 600 062, Tamil Nadu, India.



Ionotropic glutamate receptors, Docking, Dopamine, 6-hydroxydopamine, L-Glutamate, L-beta-oxalyl-amino-alanine


Objectives: Ionotropic glutamate receptors (iGluRs) play a key role in the development and function of the nervous system. They also play an important in memory and learning process. They are implicated in various pathological conditions such as Alzheimer's, Epilepsy, Huntington's, and Parkinson's diseases. This prompted us to carry out the present study on 13 selected compounds.

Methods: These 13 compounds were evaluated on the docking behavior of iGluR-2 (iGluR2) using PatchDock. In addition, molecular physicochemical, drug-likeness, absorption, distribution, metabolism, and excretion analyses were also carried out.

Results: The molecular physiochemical analysis revealed that all the 13 ligands showed nil violation and complied well with the Lipinski's rule of five. ADME analysis showed that all the ligands (except ligands 1 and 12) predicated to have high gastrointestinal absorption property. Docking studies revealed that ligand 8 (dopamine) showed the highest atomic contact energy (ACE) (−78.14 kcal/mol), while ligand 9 (6-hydroxydopamine) showed the least ACE (−14.34 kcal/mol) with that of iGluR2. Similarly, ligand 8 (dopamine) has shown to interact with Ser 142 amino acid residue of iGluR2.

Conclusion: Thus, the present study showed the potential of 13 compounds as a modulator of iGluR-2.


Download data is not yet available.


Kaczor AA, Matosiuk D. Molecular structure of ionotropic glutamate receptors. Curr Med Chem 2010;17:2608-35.

Naur P, Hansen KB, Kristensen AS, Dravid SM, Pickering DS, Olsen L, et al. Ionotropic glutamate-like receptor delta2 binds D-serine and glycine. Proc Natl Acad Sci U S A 2007;104:14116-21.

Serafimoska Z, Johansen TN, Frydenvang K, Suturkova L. Ionotropic glutamate receptors (iGluRs): Overview of iGluR2 ligand binding domain in complex with agonists and antagonists. Maced Pharm Bull 2011;57:3-16.

Ankulu M, Aparna.N, Raju NV, Arjun LK. Putative ligand-target docking studies of human AMPA selective ionotropic glutamate receptors reveal that β-ODAP has high binding affinity compared to tyrosine and glutamate. Int Res J Biochem Bioinform 2013;3:130-9.

Daina A, Michielin O, Zoete V. Swiss ADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.

Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and symmDock: Servers for rigid and symmetric docking. Nucleic Acids Res 2005;33:W363-7.

Olney JW, Ho OL, Rhee V. Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system. Exp Brain Res 1971;14:61-76.

Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431-568.

Pai KS, Ravindranath V. L-BOAA induces selective inhibition of brain mitochondrial enzyme, NADH-dehydrogenase. Brain Res 1993;621:215-21.

Jiang L, Kiselova N, Rosén J, Ilag LL. Quantification of neurotoxin BMAA (β-N-methylamino-L-alanine) in seafood from Swedish markets. Sci Rep 2014;4:6931.

Rohini D, Vijayalakshmi K. Sesamol antagonizes rotenone-induced cell death in SH-SY5Y neuronal cells. Int J Pharm Pharm Sci 2016;8:72-7.

Priyanga KS, Vijayalakshmi K, Selvaraj R. Behavioral studies of wistar rats in rotenone induced model of parkinson’s disease. Int J Pharm Pharm Sci 2017;9:159-64.

Merino P, Lanaspa A, Merchan FL, Tejero T. Stereocontrolled synthesis of 2, 3-diaminobutanoic acids. Tetrahedron Lett 1997;38:1813-6.

Kobylarz MJ, Grigg JC, Shin-ichi JT, Rai DK, Heinrichs DE, Murphy ME. Synthesis of L-2, 3-diaminopropionic acid, a siderophore and antibiotic precursor. Chem Biol 2014;21:379-88.

Craighead D, Metcalf JS, Banack SA, Amgalan L, Reynolds HV, Batmunkh M. Presence of the neurotoxic amino acids β-N-methylamino-L-alanine (BMAA) and 2, 4-diamino-butyric acid (DAB) in shallow springs from the Gobi Desert. Amyotroph Lateral Scler 2009; 10 sup2:96-100.

Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson’s disease. Neurotox Res 2007;11:151-67.

D’Aniello S, Fisher GH, Topo E, Ferrandino G, Garcia-Fernà ndez J, D’Aniello A, et al. N-methyl-D-aspartic acid (NMDA) in the nervous system of the amphioxus branchiostoma lanceolatum. BMC Neurosci 2007;8:109.

Ganesan K, Sukalingam K, Balamurali K, Alaudeen SR, Ponnusamy K, Ariffin IA, et al. A studies on monosodium l-glutamate toxicity in animal models-a review. Int J Pharm Chem Biol Sci 2013;3:1257-68.

Shang T, Uihlein AV, Van Asten J, Kalyanaraman B, Hillard CJ. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J Neurochem 2003;85:358-67.

Wang J, Urban L. The impact of early ADME profiling on drug discovery and development strategy. DDW 2003;5:73-96.

Bonnet CS, Williams AS, Gilbert SJ, Harvey AK, Evans BA, Mason DJ, et al. AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Ann Rheum Dis 2015;74:242-51.

Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999;51:7-61.

Mayer ML, Armstrong N. Structure and function of glutamate receptor ion channels. Annu Rev Physiol 2004;66:161-81.



How to Cite

Narayanaswamy, R., and M. Hailu. “MOLECULAR DOCKING ANALYSIS OF THIRTEEN COMPOUNDS AS MODULATOR OF IONOTROPIC GLUTAMATE RECEPTOR”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 11, Nov. 2018, pp. 114-7, doi:10.22159/ajpcr.2018.v11i11.27602.



Original Article(s)